Gilead Sciences, Inc. $GILD Shares Purchased by Howard Capital Management Inc.

Howard Capital Management Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,094 shares of the biopharmaceutical company’s stock after buying an additional 5,702 shares during the quarter. Howard Capital Management Inc.’s holdings in Gilead Sciences were worth $4,334,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the 1st quarter worth $25,000. Activest Wealth Management lifted its stake in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. GoalVest Advisory LLC boosted its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences in the second quarter valued at about $27,000. Finally, Colonial Trust Advisors grew its stake in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on GILD shares. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research report on Tuesday, August 19th. Cantor Fitzgerald boosted their target price on shares of Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. TD Cowen raised their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $122.61.

Gilead Sciences Trading Down 0.4%

GILD opened at $120.47 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $124.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a market capitalization of $149.48 billion, a PE ratio of 24.00, a P/E/G ratio of 0.83 and a beta of 0.34. The firm’s fifty day moving average price is $115.52 and its 200 day moving average price is $111.21.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the sale, the insider owned 110,193 shares in the company, valued at $13,011,589.44. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the transaction, the chief financial officer directly owned 157,055 shares in the company, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,500 shares of company stock valued at $7,142,140 over the last three months. 0.27% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.